跳至主要内容
临床试验/ISRCTN47673027
ISRCTN47673027终止未知

Minimising the risks of emergence of antibiotic resistance during therapy by precise regimen individualisation and use of combination therapy

orth Bristol NHS Trust0 个研究点目标入组 80 人开始时间: 2022年4月26日最近更新:
适应症

试验速览

阶段
未知
状态
终止
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Intubated patients with clinician suspected Gram-negative pulmonary infection requiring antibacterial therapy
  • 2. Adults aged 18 years upwards
  • 3. Patient admitted to ICU for at least 5 days
  • 4. Patient ventilated for at least 48 hours
  • Inclusion criteria for analysis:
  • Infection with a piperacillin-tazobactam and gentamicin susceptible Gram-negative organism.

排除标准

  • 1. Patients for whom informed consent cannot be obtained
  • 2. Allergies or intolerance to piperacillin-tazobactam or gentamicin
  • 3. Neutropaenic sepsis
  • 4. Past medical history of cystic fibrosis
  • 5. Other underlying infections pulmonary process unlikely to respond to piperacillin/tazobactam with or without gentamicin (i.e. tuberculosis, fungal pneumonia)
  • 6. Subject unlikely to survive longer than 24 hours
  • 7. Prisoners
  • 8. Pregnant women
  • 9. Non-NHS patients

研究者

发起方
orth Bristol NHS Trust

相似试验